Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Adaptimmune Therapeutics PLC Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

$100 Billion
Q4 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$1.33 - $2.28 $98,760 - $169,303	-74,256 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$1.73 - $4.06 $8,850 - $20,770	5,116 Added 7.4%	74,256 $153,000
Q4 2021 Feb 07, 2022	BUY	$3.5 - $5.68 $29,022 - $47,098	8,292 Added 13.63%	69,140 $281,000
Q2 2021 Aug 06, 2021	SELL	$3.86 - $5.78 $62,037 - $92,896	-16,072 Reduced 20.89%	60,848 $259,000
Q1 2021 May 06, 2021	BUY	$4.9 - $6.83 $127,463 - $177,668	26,013 Added 51.1%	76,920 $408,000
Q4 2020 Feb 09, 2021	BUY	$4.0 - $9.2 $203,628 - $468,344	50,907 New	50,907 $274,000
Q2 2019 Aug 08, 2019	SELL	$3.23 - $5.41 $92,445 - $154,839	-28,621 Closed	0 $0
Q1 2019 Apr 26, 2019	BUY	$3.63 - $6.06 $8,276 - $13,816	2,280 Added 8.66%	28,621 $123,000
Q4 2018 Feb 08, 2019	BUY	$3.76 - $14.16 $57,757 - $217,511	15,361 Added 139.9%	26,341 $141,000
Q3 2018 Nov 13, 2018	BUY	$8.27 - $13.56 $90,804 - $148,888	10,980 New	10,980 $149,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

123M

Call Options Held

34.2K

Put Options Held

16.3K

Eco R1 Capital, LLC San Francisco, CA

27.4M
Shares

$12.3 Million
0.69% of portfolio
Long Focus Capital Management, LLC San Juan, PR

20.5M
Shares

$9.22 Million
0.38% of portfolio
Nea Management Company, LLC Timonium, MD

17.1M
Shares

$7.69 Million
0.66% of portfolio
Two Seas Capital LP Rye, NY

14.8M
Shares

$6.68 Million
1.31% of portfolio
Baillie Gifford & CO

11.8M
Shares

$5.32 Million
0.01% of portfolio

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $73.5M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Account